Neurogastrx was founded to address unmet needs of functional and motility gastrointestinal (GI) disorders, which are disorders of GI function, affecting gut contractions, sensation and the brain-gut axis.
Functional bowel disorders present a major health problem in the United States. Upper gastrointestinal dysmotility, irritable bowel syndrome, and constipation each represent multi-billion dollar markets: 2 percent of Americans (>5 million) report having irritable bowel syndrome; constipation affects another 3 percent of the general population; 14 percent of the US population reports reflux symptoms on a weekly basis; and 20 percent of diabetic patients have Gastroparesis. Gastroparesis is also prominent in other patient populations such as Parkinson’s disease where it affects the pharmacokinetics as well as the overall bioavailability of therapies for the treatment of motor symptoms (levodopa).
Despite their widespread prevalence, there are only a few approved prescription drugs available for this group of disorders, all of which are either not target-based or come at the cost of serious side-effects such as metoclopramide (Reglan) or domperidone (Motilium).